2016 American Transplant Congress
A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results.
1U Of Cincinnati, Cincinnati; 2Mayo Clinic, Phoenix.
Carfilzomib (CFZ) is mechanistically distinct from bortezomib as it is an irreversible PI. Results from phase 1 of a CFZ desensitization (DS) trial are presentedMethods:…2016 American Transplant Congress
Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.
Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands.
The Eurotransplant Acceptable Mismatch (AM) program has been initiated 25 years ago in order to enhance transplantation of highly sensitized renal transplant candidates. Instead of…2016 American Transplant Congress
Allo-Specific Memory B Cell Recall Responses Are Dependent on B Cell Autophagy.
B cells, and in particular, memory B cells (Bmem) are sources of donor specific antibodies (DSA) that cause allograft injury. Understanding requirements for Bmem function/survival…2015 American Transplant Congress
Blocking CD4 T Cell Helper Functions Improves Efficacy of ATG Treatment in Sensitized Transplant Recipients
Immunology, Cleveland Clinic, Cleveland, OH.
Antibody mediated lymphocyte depletion is used in clinical transplantation to improve graft function. While the presence of donor-reactive memory T cells is the primary rationale…2015 American Transplant Congress
Combined Anti-IL6R and CTLA4Ig Therapy Attenuates Recall Alloantibody Responses in a Mouse Model of HLA Sensitization
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
[bald]Background[/bald] We previously reported that IL-6 inhibition by anti-IL6R antibody (mMR16-1) or CD28 pathway inhibition using CTLA4Ig (abatacept) reduced recall alloantibody responses in a mouse…2015 American Transplant Congress
Differential Clinical Outcomes in Kidney Transplant Recipients With De Novo C1q+ and C1q- Donor Specific Antibodies
Background: We investigated the prevalence and clinical significance of C1q binding versus non-C1q binding de novo DSA in kidney transplant recipients.Methods: The study group included…2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…2015 American Transplant Congress
Costimulation Blockade and Bortezomib to Desensitize Rhesus Macaque and Prolong Renal Allograft Survival
Surgery, Emory Transplant Center, Atlanta, GA.
[Background] Preformed donor specific antibody (DSA) due to prior sensitization affects a significant population of transplant patients, portending a poorer prognosis in short- and long-term…2015 American Transplant Congress
Desensitization Before Living Donor Kidney Transplantation in Highly Sensitized Patients
Renal transplantation in highly sensitized patients represents a major clinical challenge leading to long periods in the waiting list. When a living donor is available,…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »